(-0.58%) 5 078.00 points
(-0.40%) 38 526 points
(-0.87%) 17 510 points
(0.04%) $82.84
(-0.30%) $1.648
(0.00%) $2 338.30
(0.16%) $27.39
(-0.01%) $915.70
(-0.24%) $0.932
(-0.29%) $10.95
(-0.41%) $0.799
(-0.26%) $92.08
Live Chart Being Loaded With Signals
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia...
Stats | |
---|---|
Today's Volume | 28.03M |
Average Volume | 11.93M |
Market Cap | 31.43M |
EPS | $0 ( 2024-02-29 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.600 |
ATR14 | $0 (0.00%) |
Alterity Therapeutics Ltd Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Alterity Therapeutics Ltd Financials
Annual | 2023 |
Revenue: | $3.92M |
Gross Profit: | $3.63M (92.72 %) |
EPS: | $-0.00570 |
Q2 | 2024 |
Revenue: | $1.90M |
Gross Profit: | $1.83M (96.11 %) |
EPS: | $-0.00260 |
Q4 | 2023 |
Revenue: | $1.53M |
Gross Profit: | $1.48M (96.58 %) |
EPS: | $-0.00240 |
Q3 | 2022 |
Revenue: | $765 247 |
Gross Profit: | $702 730 (91.83 %) |
EPS: | $-0.00120 |
Financial Reports:
No articles found.
Alterity Therapeutics Ltd
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators